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The HLA-G molecule is a member of the non-classical HLA class I family. Its surface 
expression is physiologically restricted to the maternal–fetal interface and to immune 
privileged adult tissues. Despite the restricted tissue expression, HLA-G is detectable in 
body fluids as secreted soluble molecules. A unique feature of HLA-G is the structural 
diversity as surface expressed and as secreted molecules. Secreted HLA-G can be found 
in various body fluids either as free soluble HLA-G or as part of extracellular vesicles (EVs), 
which are composed of various antigens/ligands/receptors, bioactive lipids, cytokines, 
growth factors, and genetic information, such as mRNA and microRNA. Functionally, 
HLA-G and its secreted forms are considered to play a crucial role in the network of 
immune-regulatory tolerance mechanisms, preferentially interacting with the cognate 
inhibitory receptors LILRB1 and LILRB2. The HLA-G mediated tolerance is described 
in processes of pregnancy, inflammation, and cancer. However, almost all functional 
and clinical implications of HLA-G in vivo and in vitro have been established based on 
simple single ligand/receptor interactions at the cell surface, whereas HLA-G-bearing 
EVs were in minor research focus. Indeed, cytotrophoblast cells, mesenchymal stem 
cells, and cancer cells were recently described to secrete HLA-G-bearing EVs, display-
ing immunosuppressive effects and modulating the tumor microenvironment. However, 
numerous functional and clinical open questions persist. Here, we (i) introduce basic 
aspects of EVs biology, (ii) summarize the functional knowledge, clinical implications and 
open questions of HLA-G-bearing EVs, and (iii) discuss HLA-G-bearing EVs as a future 
element in HLA-G biology.
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iNtrODUctiON
HLA-G is a non-classical HLA class I molecule. It is a potent suppressive molecule that impairs 
effector functions of immune cells belonging to the innate and adaptive immune system. Under 
physiological conditions, its surface expression is restricted to the maternal–fetal interface and to 
immune privileged adult tissues (1). However, secreted soluble forms of HLA-G are detectable in 
a variety of body fluids such as peripheral blood and amniotic fluids (2), malignant ascites (3, 4), 
2Rebmann et al. HLA-G-Bearing Extracellular Vesicles
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 173
pleural effusions (5), cerebrospinal fluid (6, 7), and sperm (8). 
Neo-ectopic or aberrant expression of HLA-G has frequently 
been related to malignancies (9–13), viral infections (14–19) 
including liver-related hepatitis B (16) and C (18) virus infec-
tions, autoimmune disorders (20–22), inflammatory diseases 
(23), complications (24, 25), and transplantation outcomes 
(26, 27).
A unique feature of HLA-G is that it exists in multiple struc-
tures, either expressed on the cell surface or in a secreted form. 
These different forms can mainly be attributed to alternative 
splicing of the primary transcript and differential association 
with β2-microglobulin (β2m). Four isoforms (HLA-G1, G2, G3, 
and G4) are membrane-expressed and three isoforms express 
either intron 4 (HLA-G5 and -G6) or intron 2 (HLA-G7) but 
lack the transmembrane and cytoplasmic domains, resulting in 
their secretion. With the exception of HLA-G3 (28), all HLA-G 
structures can create disulfide bounds between two unique 
cysteine residues at positions 42 (Cys42–Cys42 bonds) and 147 
(Cys42–Cys147 bonds) (29, 30). The structures displaying the 
full-length extracellular domain (HLA-G1 and HLA-G5) are 
probably the most frequently detected. The structural diversity is 
further enhanced in that all membrane-expressed structures can 
also be shed from cell surface by metalloproteases (31) or can be 
secreted via extracellular vesicles (EVs) (32).
Regarding function, HLA-G and the soluble counterparts 
preferentially exert their immune modulating or suppressing 
functions by interaction with the two inhibitory receptors, 
leukocyte immunoglobulin-like receptor subfamily B member 1 
(LILRB1) and LILRB2. LILRB1 is expressed on subpopulations 
of T-cells, B-cells, and Natural Killer (NK) cells. Monocytes/
macrophages/dendritic cells (DC) express both receptors. These 
two receptors distinguish between β2m-associated and β2m-free 
HLA-G: LILRB1 interacts with HLA-G molecules associated to 
β2m, whereas LILRB2 specifically recognizes β2m-free HLA-G 
(33, 34). HLA-G dimers bind to LILRB with a higher affinity 
and avidity than monomers, resulting in more efficient LILRB-
mediated signaling (35, 36). Additionally, HLA-G has been 
described to be the sole ligand for the killer immunoglobulin-like 
receptor 2DL4 (KIR2DL4), exhibiting both an activating and an 
inhibitory signaling domain. Moreover, soluble forms of HLA-G 
are able to trigger apoptosis in CD8+ T and NK cells (37) as well 
as in CD160-bearing endothelial cells (38).
Based on the functionality of receptors and their expression 
profile, membrane-expressed and soluble forms of HLA-G 
molecules are involved in immune regulation in pregnancy, 
inflammation, and cancer. Thus, HLA-G can be considered 
as an immune checkpoint molecule (39). However, most 
functional implications of HLA-G in  vivo and in  vitro have 
been deduced from the HLA-G1 and HLA-G5 structures and 
from a rather simple point of view on single ligand/receptor 
interaction. Interaction of target cells with HLA-G-bearing 
EVs has typically not been considered. Here, we (i) introduce 
basic aspects of EVs biology, (ii) summarize the current 
knowledge and open questions of HLA-G-bearing EVs, and 
(iii) discuss HLA-G-bearing EVs as a future element in the 
HLA-G biology.
BAsic AsPects OF ev BiOLOGY
common Features of  
extracellular vesicles
Extracellular vesicles are phospholipid bilayer-enclosed vesicles, 
which are released by most cell types, including immune cells, 
tumor cells, stroma cells, trophoblast cells, and adult and embry-
onic stem cells (40). Depending on the cell of origin, state, and 
micro-environment, EVs are highly heterogeneous in size, mem-
brane composition, and molecular content. According to biogen-
esis, EVs are specified as exosomes (70–150 nm), microvesicles 
(100–1000 nm), and apoptotic bodies (AB) (>500 nm). Exosomes 
correspond to intraluminal vesicles (ILVs), formed from inward 
budding of small-sized plasma membrane and enclosed in multi-
vesicular bodies (MVB). Exosomes are released into extracellular 
space after fusion of MVB with the plasma membrane (41). In 
contrast, microvesicles (MV) are formed by outward budding and 
sission of the plasma membrane. AB are generated from plasma 
membrane blebs of cells undergoing apoptosis. Oncosomes, 
which are generated by the shedding of plasma membrane blebs 
of non-apoptotic cancer cells (42), and form an atypically large 
EV population (1,000–10,000 nm). Several proteins are currently 
used as markers for EVs, including tetraspanins, different heat 
shock proteins, adhesion molecules, cytoskeletal proteins, and 
members of endosomal sorting complexes required for transport 
of exosomes like TSG101 (43, 44). However, so far, no specific 
markers have been identified allowing for the identification of 
particular EV subpopulations (44).
Different cell types release differently assembled EV. 
Furthermore, it is tempting to speculate that even individual cells 
release different EV types. Importantly, the cell of origin controls 
the molecular composition and cargo (45–48). EVs harbor 
various types of antigens, cell surface-expressed receptors or 
ligands including classical and non-classical HLA-G (32, 49–53), 
bioactive lipids such as prostaglandins (54) and leukotrienes (55). 
Additionally, EVs can serve as transport cassettes or a dissemi-
nated storage pool of bioactive effector molecules, e.g., cytokines 
transcription factors, growth factors, oncogenic proteins, and 
genetic information such as mRNA, microRNA (56–59). Here, 
the lipid membrane of EVs protects their contents against enzyme 
degradation present in body fluids and thereby facilitate the 
transfer of their cargo over a short or long distance.
Modes of interaction between 
extracellular vesicles and target cells
The composition of EVs is responsible for the biodistribution, for 
the interaction of EVs to target cells or to extracellular matrix. 
Membrane fusion of EVs to target cells allows the transfer of 
bioactive molecules, including, e.g., CCR5 (60) and EGFRvIII 
(61), modifying the recipient cell phenotype. However, the 
direct fusion of EVs with the plasma membrane of effector cells 
requires a similar fluidity of the two fusing membranes. This can 
be achieved in an acidic micro-environment, which naturally 
occurs inside tumors (62–65) or at neutral pH in the presence of 
syncythin (66).
tABLe 1 | source of HLA-G-bearing evs with potential immunological and clinical relevance.
cell type evs source Potential target cell 
response
Function/mechanism clinical relevance reference
Melanoma Tolerance-inducing effect of 
melanoma derived  
HLA-G-bearing EVs on  
immune cells
Potential induction of 
inhibitory signaling by 
HLA-G1-bearing EVs via 
LILRB1/2 receptors
Unknown clinical relevance (32)
Kidney cancer Inhibitory effect of  
HLA-G-bearing EVs on 
monocyte differentiation into 
mature DCs and reduced T 
cell proliferation
Inhibitory effect of  
HLA-G1-bearing EVs on 
monocyte differentiation 
and their maturation to DCs
Suppression of immune effector 
cells by HLA-G1-bearing EVs, 
leading to disease progression
(83)
Breast cancer Modulation of immune effector 
functions by circulating  
HLA-G-bearing EVs
Unknown function Association of high circulating 
amounts of HLA-G-bearing EVs 
to disease progression
(84)
Trophoblast Modulation of immune effector 
functions by cytotrophoblast-
derived HLA-G5-bearing EVs
Unknown function Unknown clinical relevance, 
but potential biomarker for 
pregnancy-related disorders
(87)
Mesenchymal 
stem/stromal 
cells (MSCs)
Induction of tolerance between 
graft and host immune cells by 
MSCs-derived EVs
Immunomodulation by 
synergistic additive effect 
of HLA-G, IL-10, and TGFβ
Potential therapeutic option for 
patients with therapy–refractory 
GvHD using MSC-derived  
HLA-G-bearing EVs
(91)
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Besides membrane fusion, EVs can be internalized by dif-
ferent pathways including phagocytosis, clathrin- and caveolin- 
mediated endocytosis, or micropinocytosis (67). With the excep-
tion of the latter, the uptake and internalization of EVs are mostly 
receptor-mediated, e.g., via Hsp90 receptor or scavenger receptor 
CD36 (66). The expression of adhesion molecules on EVs prob-
ably facilitates the specific uptake of EVs, and their internalization 
by their cognate receptors being expressed on certain tissue or cell 
populations (68). The internalization of EVs results in the deliv-
ery and enrichment of bioactive molecules into the target cell’s 
endosomes. Hence, these molecules may be forwarded to other 
cell compartments, where they may contribute to an intracellular 
signaling mechanism.
the immunological Potential of 
extracellular vesicles
The communication and immune modulation by EVs take place 
among cells within same entity or between different types of cells. 
Various effector cells of the innate and adaptive immune system, 
including T cells and NK cells, antigen presenting cells (APCs), 
and mast cells have been reported to donate or to acquire ligand/
receptor/genetic information via EVs. Due to the complex and 
often antagonistic composition, EVs can mediate gene expression 
modification, immune activating or immune suppression, intro-
ducing homeostasis or immune tolerance by the induction of 
T cell apoptosis, impairment of DC maturation, or the prevention 
of NK and T cell cytotoxicity (68–76). Furthermore, the molecular 
transfer of miRNA by EVs can alter the expression profile of the 
recipient cell (71). Tumor-derived EVs can stimulate immune 
suppression and tumor progression in different ways including 
the inhibition of tumor-specific T cell function and proliferation 
(77), the promotion of regulatory T cells subsets (78), and transfer 
of oncogenic receptors (61).
tHe cUrreNt stAtUs AND OPeN 
QUestiONs OF HLA-G-BeAriNG 
eXtrAceLLULAr vesicLes
HLA-G-Bearing evs and cancer
Without any doubt, the neo-ectopic expression of HLA-G mol-
ecules either on the surface of tumor cells or released as soluble 
forms can be considered a critical factor for cancer progres-
sion. Albeit high blood levels of soluble forms of HLA-G have 
concordantly been related to cancer, the prognostic relevance 
of soluble HLA-G in the blood has not always been established 
as an independent marker in terms of disease progression and 
survival (39). To date, the source of soluble HLA-G is known. 
In addition, it is not clarified whether HLA-G-bearing EVs or 
free soluble HLA-G (sHLA-Gfree) are produced by tumor cells and 
whether both subcomponents contribute to immune evasion of 
tumor cells.
Secreted HLA-G-expressing EVs (Table 1) have been detected 
for the first time in supernatants of a melanoma cell line, origi-
nated from a HLA-G-positive melanoma lesion (32). Both, the 
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cell line cells and the secreted EVs express the full-length isoform 
HLA-G1. Up to now, it is not known whether HLA-G1-bearing 
EVs are functionally active to transduce inhibitory signals toward 
effector cells via the LILRB1/2 receptors, which may spread the 
tolerogenicity of HLA-G.
The first in vivo existence of HLA-G-bearing EVs was reported 
for ascites and pleural exudates derived from cancer patients 
(53). The EV fractions, however, contain ubiquitinated HLA-G 
molecules with atypically high HLA-G molecular sizes ranging 
from 50 to 75 kD. Generally, ubiquitination is a frequent post-
translational protein modification, by which proteins are targeted 
to protein degradation or directed to other cellular locations (79, 
80). Interestingly, EVs contain many polyubiquitinated proteins, 
which are not integrated into their membrane (81). Thus, the 
presence of secreted HLA-G5 or HLA-G6 cannot be excluded.
Very recently, we established the prognostic relevance of HLA-
G-bearing EVs for neoadjuvant chemotherapy-treated (NACT) 
breast cancer patients for the first time (82). Both, the total 
amount of HLA-Gtot and the amount of sHLA-Gfree were signifi-
cantly increased in breast cancer patients. Before NACT, sHLA-
Gfree levels are exclusively related to estrogen receptor expression, 
whereas high amounts of HLA-G in EVs (sHLA-GEV) enriched 
from peripheral blood samples are associated with the existence 
of circulating stem cell-like tumor cells. Strikingly, despite high 
amounts of sHLA-Gtot, its prognostic relevance could not be 
substantiated. However, different impacts on prognosis have been 
shown for the two subcomponents sHLA-GEV and sHLA-Gfree: 
high sHLA-GEV levels are associated with disease progression, 
whereas high sHLA-Gfree levels are related to an improved clini-
cal outcome. This suggests that some of the sHLA-Gfree molecules 
are impaired regarding LILRB1 recognition, and thereby are not 
qualified to exert inhibitory functions, as already demonstrated 
in rheumatoid arthritis patients (83). In conclusion, this study 
exemplifies the importance of stratifying soluble forms of HLA-G 
into free and EVs-bound molecules, as these two subcomponents 
can display diametrically opposed prognostic impact on disease 
progression likely due to the differential power of these com-
pounds to contribute to an immune escape of tumor cells.
Further underlining the functional relevance of HLA-G-
bearing EVs in cancer, a recent study demonstrated that (i) EVs 
released by renal cancer stem cells carry HLA-G with a HLA-G1 
typical molecular weight, (ii) these HLA-G-bearing EVs impair 
the differentiation of monocytes to mature DCs, and (iii) the 
presence of these DCs reduces the T cell proliferation. Thus, 
HLA-G-bearing EVs mediate inhibitory effects on monocyte 
differentiation and their maturation to DCs (84).
HLA-G-Bearing evs and Pregnancy
At the maternal–fetal interface, HLA-G and its soluble forms are 
expressed on both sides, on extravillous trophoblast cells lining 
the placenta and on tolerance-inducing DCs (DC-10) being 
enriched in the first trimester decidua (25, 85). Thus, HLA-G is 
thought to orchestrate the cross talk among embryo trophoblasts, 
decidual leukocytes, and stromal cells allowing the trophoblast 
invasiveness, decidual cell differentiation, vascular remodeling, 
and the reprograming of local maternal immune responses 
(86). Whether HLA-G-bearing EVs represent an additional 
instrument to mediate communication of these cells is currently 
unclear. Interestingly, both first trimester and term placentas 
have been reported to secrete HLA-G5 isoforms via EVs (87). In 
agreement with the reported immunolocalization of HLA-G (88) 
cytotrophoblast cells, but not differentiated syncytiotroblasts, are 
producing HLA-G5-positive exosomes. The observation of the 
presence of HLA-G5 in EVs raises the issue whether HLA-G5 
is associated with the luminal or with the extravesicular EV 
side. As secreted molecules, the association of HLA-G5 with 
extravesicular EV sides would require a binding partner it can 
associate with. Alternatively, the association with the luminal 
side would require the transit of HLA-G into the cytoplasma 
after biosynthesis. Independently of the immunogenicity of EVs 
and of the secretion pathway directing HLA-G5 toward EVs, it 
is clear that HLA-G5 isoforms being inside of EVs are hidden, 
which provokes questions about the function of HLA-G5 in 
cytotrophoblast-derived EVs.
HLA-G-Bearing evs and Mesenchymal 
stem/stromal cells
Similar to trophoblast cells, mesenchymal stem/stromal cells 
(MSCs) express surface-expressed and soluble forms of HLA-G, 
which are involved in the suppression of T and NK cell func-
tions (89). Besides HLA-G, MSCs exert the immune regulatory 
and modulatory activities through a variety of soluble media-
tors such as IL10, TGFβ, either as free soluble molecules or via 
immunological active EVs (90). The latter have been suggested to 
mediate synergistical effects of these molecules. In view of this, 
MSC-derived EVs, containing huge amounts of HLA-G, IL-10 
and TGFβ, were used to treat a patient suffering from severe and 
therapy–refractory cutaneous and intestinal GvHD grade IV 
(91). After serial application rounds of MSC-EVs, a substantial 
improvement of the clinical GvHD symptoms has been achieved 
without any side-effects. Simultaneously, the allogeneic cytokine 
responsiveness of the patient’s peripheral mononuclear blood cells 
was substantially reduced. Although a direct impact of HLA-G on 
the immune suppression has not been demonstrated, this study 
represents the first treatment in humans, in which HLA-G with 
the immune modulatory function of MSC-derived EVs has been 
applied. Thus, it triggered significant interest in applying EVs-
based therapeutics in clinical trials (92).
New Perspectives of HLA-G-Bearing 
extracellular vesicles
Currently, the known functions of HLA-G are restricted to recep-
tors expressed on the surface of effector cells of the innate and 
adaptive immune system. In this way, HLA-G inhibits the cyto-
lytic function of NK cells (93, 94), the antigen-specific cytolytic 
function of cytotoxic T lymphocytes (CTL) (95) and γ/δ T cells 
(96), the allogeneic proliferative response (95), and proliferation 
of CD4+ T cells (97). HLA-G also impairs the maturation and 
function of DC (98, 99). Furthermore, HLA-G is related to regu-
latory cells including regulatory T cells (89, 100–102), regulatory 
DC (103), and myeloid-derived suppressor cells (104). Due to 
the differential composition of EVs, other compounds of the 
EVs may potentiate or abrogate the functional power of HLA-G. 
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Additionally, EVs harboring HLA-G may allow the interaction 
with target cells lacking the surface expression of HLA-G specific 
receptors.
Membrane fusion of EVs to target cells can represent a possible 
mode of how HLA-G can be transferred to target cells. In this con-
text, it is noteworthy that a cellular translocation of HLA-G from 
APCs to activated T cells (102) and from tumor cells to T/NK cells 
has been reported (105, 106). The acquisition of HLA-G reverses 
the function of   T and NK cells to regulatory cells impairing 
allo-immune responsiveness. Such a spatiotemporal mechanism 
is suggested to be an instrument for “emergency” immune sup-
pression used by HLA-G-expressing tissues to protect themselves 
against aggressive immune intervention (102). It is tempting to 
speculate that EVs mediate a transfer of HLA-G to effector cells, 
which would abrogate at least the regional mode of action.
Independent of the pathway, internalization of  HLA-G-bearing 
EVs provides the opportunity for HLA-G to participate in yet 
unknown intracellular pathways. Interestingly, both soluble HLA-
G5 and shed HLA-G1 have been reported to be bound by the 
transiently expressed KIR2DL4 receptor and to be endocytosed 
into early endosomes of NK cells (107–109). This leads to the acti-
vation of a nuclear factor-κB-pathway and finally to the transcrip-
tion of pro-inflammatory and proangiogenic factors. Thus, the 
sustained endosomal signaling by KIR2DL4/HLA-G may allow 
NK cell activation despite a potential dominant inhibitory recep-
tor–ligand interaction at cell surface. In context with the secre-
tion of HLA-G by fetal trophoblast cells, this NK cell-mediated 
mechanism has been discussed to be operative in the promotion 
of vascularization in maternal decidua during early pregnancy 
(107–109). Here the question arises, whether this KIR2DL4–
HLA-G pathway becomes operative when fetal trophoblast cells 
secrete HLA-G-bearing EVs or whether other yet unknown 
receptors can mediate intercellular signaling. The investigation 
of molecular signature molecules on  HLA-G-bearing EVs may 
help to provide an insight into the functional consequence and 
the intracellular signaling pathway after internalization (69).
Regarding the role of HLA-G in diagnosis, prognosis, and 
treatment, the cell-specific signature of HLA-G-bearing EVs may 
not only provide information about the potential target cells and 
about its potential interplay of the cognate receptor/ligand on tar-
get cells but also about the cells producing these EVs (110). In that 
way, the identification of the cellular source on HLA-G-bearing 
EVs, such as the detection of the tumor marker HER-2/neu, may 
offer unforeseen diagnostic opportunities to monitor the systemic 
health status/disease status and disease activity/progression.
cONcLUsiON
It is well established that tumor cells, cytotrophoblast cells, and 
MSCs secret HLA-G-bearing EVs in addition to non-vesicular 
soluble HLA-G. All of these cell types are highly capable of pro-
moting immune tolerance and tissue remodeling. Mechanisms 
and functional consequences of HLA-G-bearing EVs and their 
specific contribution to the biology of these cells have yet to be 
determined. So far, the classical concept of HLA-G function is 
based on the interaction of HLA-G with receptors being expressed 
on the cell surface membrane. EVs, however, may serve as a ticket 
for HLA-G to interact directly with cells or to enter into the 
inside of cells. The internalization of HLA-G may introduce new 
pathways or yet unknown cognate receptors, by which HLA-G 
contributes to intracellular communication. In that way, HLA-G-
bearing EVs are likely to represent an important element in the 
biology of HLA-G.
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